Hernández-Reyes J, Galo-Hooker E, Ruiz-Delgado GJ, Ruiz-Argüelles GJ

Language: English
References: 20
Page: 604-608
PDF size: 218.88 Kb.

ABSTRACT

Material and methods. In a 30-year period in a single institution, 23 cases of systemic immunoglobulin light chain amyloidosis (AL) were identified, within a group of 1,388 individuals with some form of a hematological malignancy. Results. AL is 14 times less frequent in Mexico than in Caucasians and it represents 15% of all monoclonal gammopathies. Median age was 57 years (range 39-98); there were 11 males and 12 females. The histologic diagnosis was done in the periumbilical fat in 39%, the bone marrow in 30%, the kidney in 13%, the gastrointestinal tract in 13% and in a lymph node in one case. The nephrotic syndrome was present in 61% of cases, heart failure in 35%, sensorimotor peripheral neuropathy in 26% and weight loss in 6%. Anemia was present in 14% of cases at diagnosis; median hemoglobin was 11 g/dL. An abnormal monoclonal spike in the peripheral blood was present in 70% of cases; it had a median of 1.2 g/dL (range 0.2-3.6); there were 7 cases of light-chain only disease and five in whom an abnormal paraproteinemia was not found. Six cases were associated with overt multiple myeloma. Seventeen individuals (74%) were followed for more than 3 months (range 90 to 5190 days, median 210); their overall survival (OS) was 71% at 173 months, whereas the median OS has not been reached, being above 173 months. Eight patients were treated with melphalan/predisone and five were given high dose chemotherapy and an autologous stem cell transplantation; the others were given other treatments. Conclusions. AL is less frequent in Mexican mestizos and probably underrecognized; the clinical features of the disease are not significantly different from those informed from other populations.

REFERENCES

1. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 2011; 29(14): 1924-33.

2. Ruiz Delgado GJ, Gomez Rangel D. Gamopatía monoclonal de significado indeterminado en mestizos mexicanos: experiencia de una sola institución. Gac Med Mex 2004; 140(4): 375-9.

3. Ruiz-Delgado GJ, Ruiz-Argüelles GJ. Genetic predisposition for monoclonal gammopathy of undetermined significance. Mayo Clin Proc 2008; 83: 601-03.

4. Ruiz-Argüelles GJ, Ruiz-Delgado GJ. On the prevalence and genetic predisposition of monoclonal gammopathy of undetermined significance (MGUS). Int J Hematol 2012; 96: 144-5.

5. Ruiz-Argüelles GJ, Gomez-Rangel D, Ruiz-Delgado GJ, Aguilar- Romero L. Multiple myeloma in Mexico: a 20-year experience at a single institution. Arch Med Res 2004; 35: 163-7.

6. Ruiz-Argüelles GJ, Ramirez-Cisneros FJ, Flores-Martinez J, Cernuda-Graham MC. Waldenstrom’s macroglobulinemia is infrequent in Mexican Mestizos: experience of a hematological diseases referral center. Rev Invest Clin Mex 2000; 52: 497-9.

7. Cohen AD, Comenzo RL. Systemic light-chain amyloidosis: Advances in diagnosis, prognosis, and therapy. Hematology Am Soc Hematol Educ Program 2010; 2010: 287-94.

8. Myeloma Trialist Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. J Clin Oncol 1998; 16: 3832-42.

9. Segeren CM, Sonneveld P, van der Holt B, Baars JW, Biesma DH, Cornellissen JJ, Croockewit AJ, et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol 1999; 105: 127-30.

10. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, Geyer S, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319-23.

11. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Pérez-Romano B, Marín- López A, Delgado-Lamas JL. Non-cryopreserved peripheral blood stem cells autotransplants for hematological malignancies can be performed entirely on an outpatient basis. Am J Hematol 1998; 58: 161-4.

12. López-Otero A, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. A simplified method for stem cell autografting in multiple myeloma: A single institution experience. Bone Marrow Transplant 2009; 44: 715-9.

13. Bladé J, Kyle RA. Monoclonal gammopathies of undetermined significance. In: Malpas JS, Bergsagel DE, Kyle RA (eds.). Myeloma Biology and Management. New York: Oxford University Press; 1995.

14. Gertz MA, Dispenzieri A. Immunoglobulin light-chain amyloidosis: Growing recognition, new approaches to therapy and active clinical trials. Oncology (Williston Park) 2012; 26: 152-61.

15. Ruiz-Argüelles GJ, García-Herrera JL. Amiloidosis primaria: Desaparición del síndrome nefrótico con melfalán y prednisona. Rev Mex Patol Clin 1985; 32: 143-6.

16. Báez-García JJ, Martínez-Hernández Magro P, Iriarte-Gallego G, Báez-Aviña JA. Spontaneous rupture of the spleen secondary to amyloidosis. Cir Cir 2010; 78(6): 533-7.

17. López L, González K, Navarrete G, Novales J, Guarneros A, Cortés B, Téllez G. Multiple myeloma and systemic amyloidosis. Int J Dermatol 2008; 47(2): 165-7.

18. Vela-Ojeda J, García-Ruiz Esparza MA, Padilla-González Y, Sánchez-Cortés E, García-Chávez J, Montiel-Cervantes L, Reyes- Maldonado E, et al. Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor. Ann Hematol 2009; 88: 59-66.

19. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30(9): 989-95.

20. Dispenzieri A, Gertz MA, Buadi F. What do I need to know about immunoglobulin light chain (AL) amyloidosis? Blood Rev 2012. [Epub ahead of print].